ABCD2 | ATP-binding cassette, sub-family D (ALD), member 2 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ABLIM3 | Actin binding LIM protein family, member 3 | Plasma proteins
| | | | | Tissue enhanced |
ADAMTS15 | ADAM metallopeptidase with thrombospondin type 1 motif, 15 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
ADAMTS4 | ADAM metallopeptidase with thrombospondin type 1 motif, 4 | Cancer-related genes Enzymes
| | | | | Tissue enhanced |
ADIRF | Adipogenesis regulatory factor | Plasma proteins
| | | | | Tissue enhanced |
ADRA1A | Adrenoceptor alpha 1A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
AKR1C2 | Aldo-keto reductase family 1, member C2 | Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
AL358333.1 | HCG2013195; Uncharacterized protein | Predicted membrane proteins
| | | | | Tissue enhanced |
ANGPT4 | Angiopoietin 4 | Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ANGPTL4 | Angiopoietin-like 4 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AOC3 | Amine oxidase, copper containing 3 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
APOLD1 | Apolipoprotein L domain containing 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
AQP7 | Aquaporin 7 | Predicted membrane proteins
| | | | | Tissue enhanced |
ARC | Activity-regulated cytoskeleton-associated protein | | | | | | Tissue enhanced |
BOK | BCL2-related ovarian killer | Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
BTNL9 | Butyrophilin-like 9 | Predicted membrane proteins
| | | | | Tissue enhanced |
C12orf39 | Chromosome 12 open reading frame 39 | Predicted secreted proteins
| | | | | Tissue enhanced |
C1QTNF1 | C1q and tumor necrosis factor related protein 1 | Predicted secreted proteins
| | | | | Tissue enhanced |
C2CD4B | C2 calcium-dependent domain containing 4B | | | | | | Tissue enhanced |
C2orf66 | Chromosome 2 open reading frame 66 | Predicted secreted proteins
| | | | | Tissue enhanced |
C3orf55 | Chromosome 3 open reading frame 55 | Predicted membrane proteins
| | | | | Tissue enhanced |
CALB2 | Calbindin 2 | Plasma proteins
| | | | | Tissue enhanced |
CD248 | CD248 molecule, endosialin | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD300LG | CD300 molecule-like family member g | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CDO1 | Cysteine dioxygenase type 1 | Enzymes
| | | | | Tissue enhanced |
CLDN5 | Claudin 5 | Predicted membrane proteins
| | | | | Tissue enhanced |
CNTFR | Ciliary neurotrophic factor receptor | Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
EBF1 | Early B-cell factor 1 | Cancer-related genes Transcription factors
| | | | | Tissue enhanced |
EBF2 | Early B-cell factor 2 | Transcription factors
| | | | | Tissue enhanced |
EBF3 | Early B-cell factor 3 | Transcription factors
| | | | | Tissue enhanced |
ECM2 | Extracellular matrix protein 2, female organ and adipocyte specific | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
EHD2 | EH-domain containing 2 | | | | | | Tissue enhanced |
ELOVL3 | ELOVL fatty acid elongase 3 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
FAM180B | Family with sequence similarity 180, member B | Predicted membrane proteins
| | | | | Tissue enhanced |
FAM47E-STBD1 | FAM47E-STBD1 readthrough | Plasma proteins
| | | | | Tissue enhanced |
FZD4 | Frizzled family receptor 4 | CD markers Disease related genes G-protein coupled receptors Potential drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
G0S2 | G0/G1switch 2 | | | | | | Tissue enhanced |
GALNT15 | UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 15 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
GCOM1 | GRINL1A complex locus 1 | | | | | | Tissue enhanced |
GFPT2 | Glutamine-fructose-6-phosphate transaminase 2 | Enzymes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
GPD1 | Glycerol-3-phosphate dehydrogenase 1 (soluble) | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
GPIHBP1 | Glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 | Predicted secreted proteins
| | | | | Tissue enhanced |
GSC | Goosecoid homeobox | Transcription factors
| | | | | Tissue enhanced |
HAS1 | Hyaluronan synthase 1 | Enzymes Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
HAS2 | Hyaluronan synthase 2 | Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
HCAR1 | Hydroxycarboxylic acid receptor 1 | G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
HRASLS5 | HRAS-like suppressor family, member 5 | | | | | | Tissue enhanced |
HRCT1 | Histidine rich carboxyl terminus 1 | | | | | | Tissue enhanced |
IL2RA | Interleukin 2 receptor, alpha | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
IL6 | Interleukin 6 (interferon, beta 2) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |